These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36034126)

  • 1. Residual reserve index modifies the effect of amyloid pathology on fluorodeoxyglucose metabolism: Implications for efficiency and capacity in cognitive reserve.
    McKenzie C; Bucks RS; Weinborn M; Bourgeat P; Salvado O; Gavett BE
    Front Aging Neurosci; 2022; 14():943823. PubMed ID: 36034126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
    Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
    Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau and amyloid biomarkers modify the degree to which cognitive reserve and brain reserve predict cognitive decline.
    McKenzie C; Bucks RS; Weinborn M; Bourgeat P; Salvado O; Gavett BE;
    J Int Neuropsychol Soc; 2023 Jul; 29(6):572-581. PubMed ID: 36039968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.
    Beyer L; Schnabel J; Kazmierczak P; Ewers M; Schönecker S; Prix C; Meyer-Wilmes J; Unterrainer M; Catak C; Pogarell O; Perneczky R; Albert NL; Bartenstein P; Danek A; Buerger K; Levin J; Rominger A; Brendel M
    Neuroimage Clin; 2019; 24():101949. PubMed ID: 31398553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive reserve predicts future executive function decline in older adults with Alzheimer's disease pathology but not age-associated pathology.
    McKenzie C; Bucks RS; Weinborn M; Bourgeat P; Salvado O; Gavett BE;
    Neurobiol Aging; 2020 Apr; 88():119-127. PubMed ID: 31980279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study.
    Motta C; Di Donna MG; Bonomi CG; Assogna M; Chiaravalloti A; Mercuri NB; Koch G; Martorana A
    Alzheimers Res Ther; 2023 Aug; 15(1):144. PubMed ID: 37649105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
    Vemuri P; Weigand SD; Przybelski SA; Knopman DS; Smith GE; Trojanowski JQ; Shaw LM; Decarli CS; Carmichael O; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Brain; 2011 May; 134(Pt 5):1479-92. PubMed ID: 21478184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perivascular Space Predicts Brain Hypometabolism of Individuals with Underlying Amyloid Pathology.
    Shi X; Zhou N; Sun B; Wu Y; Hu Y; Ning Y;
    J Alzheimers Dis; 2022; 90(3):1329-1337. PubMed ID: 36245373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau.
    McCollum LE; Das SR; Xie L; de Flores R; Wang J; Xie SX; Wisse LEM; Yushkevich PA; Wolk DA;
    Neuroimage Clin; 2021; 31():102717. PubMed ID: 34119903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
    Salvadó G; Shekari M; Falcon C; Operto G; Milà-Alomà M; Sánchez-Benavides G; Cacciaglia R; Arenaza-Urquijo E; Niñerola-Baizán A; Perissinotti A; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
    Brain Commun; 2022; 4(3):fcac134. PubMed ID: 35702732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease.
    Han SD; Gruhl J; Beckett L; Dodge HH; Stricker NH; Farias S; Mungas D;
    Brain Imaging Behav; 2012 Dec; 6(4):610-20. PubMed ID: 22648764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.
    Matthews DC; Kinney JW; Ritter A; Andrews RD; Toledano Strom EN; Lukic AS; Koenig LN; Revta C; Fillit HM; Zhong K; Tousi B; Leverenz JB; Feldman HH; Cummings J
    Alzheimers Dement (N Y); 2024; 10(3):e12490. PubMed ID: 38988416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images.
    Malotaux V; Colmant L; Quenon L; Huyghe L; Gérard T; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
    J Alzheimers Dis; 2024; 97(1):421-433. PubMed ID: 38108350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multi-Dimensional Comparison of Alzheimer's Disease Neurodegenerative Biomarkers.
    Liu Y; Han PR; Hu H; Wang ZT; Guo Y; Ou YN; Cao XP; Tan L; Yu JT;
    J Alzheimers Dis; 2022; 87(1):197-209. PubMed ID: 35275546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
    Carapelle E; Serra L; Modoni S; Falcone M; Caltagirone C; Bozzali M; Specchio LM; Avolio C
    Medicine (Baltimore); 2017 Apr; 96(16):e5876. PubMed ID: 28422821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.